Skip to main content

Table 1 Patient characteristics

From: A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases

Patients Total (n = 90) %
Gender: Female 38 42%
    Male 52 58%
Age at diagnostic, median (range): 62 years (22–82)
Age at SBRT, median (range): 65 years (23–84)
Primary sites:   Digestive 63 70%
         Lung 3 3.3%
        Breast 8 8.9%
        Melanoma 4 4.4%
        Neuro-endocrine 3 3.3%
        Sarcoma 3 3.3%
        Other 6 6.7%
Adenocarcinoma Histology: Hepatic (n = 75) 61 81%
            Lung (n = 15) 7 47%
Primary for Adenocarcinoma histology 68  
   Colorectal 57 84%
   Breast 8 12%
   Gastric 1 1.5%
   Lung 1 1.5%
   Kidney 1 1.5%
Primary for squamous cell histology : 7  
   Esophagus 5 71%
   Lung 2 29%
Other histologies : 15 17%
Lesions : Lung 15 17%
    Hepatic 75 83%
Number of lesions treated by patient :   
1 64 71%
2 19 21%
3 4 4%
4 3 3%
Timing of Metastases:   
    At initial diagnostic 43 49%
    Within one year 20 23%
    More than 1 year 25 28%
Time from diagnosis of metastasis to SBRT treatment, median (range) 25.6 months (1.2 – 93.6)
Previous local treatment :   
    Hepatic (n = 75) 53 71%
    Lung (n = 15) 0 0%
Prior chemotherapy:   91%
    Hepatic lesions (n = 75) 70 93%
    Lung lesions (n = 15) 12 92%
Prior progressive disease with Chemo:   
    No 67 82%
    Yes 15 18%
More than 3 chemotherapy regimens before SBRT :   26,6%
    Hepatic lesions (n = 75) 21 28%
    Lung lesions (n = 15) 3 20%